Genetic Variants Linked to Bleeding Risk in Warfarin Patients
the MPR take:
The first study to find an association between a gene variant and clinically significant decreased risk of major bleeding in patients taking warfarin has been published in the journal Clinical Pharmacology & Therapeutics. In evaluating 205 patients in a community setting on warfarin therapy, those with the common CYP4F2*3 variant had a 38% lower major bleeding risk compared to patients without this variant. This suggests that testing for CYP4F2*3 status could be important for personalizing treatment, particularly since an increased dose is needed for patients with the variant to achieve therapeutic INR levels.
READ FULL ARTICLE From Nature